Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326232 | 1.00 | FUCA1 (0.47) | FUCA1CCR5GAAHTTPAX8 | |
| SCHEMBL24326249 | 1.00 | FUCA1 (0.47) | FUCA1CCR5GAAHTTPAX8 | |
| SCHEMBL24326686 | 0.81 | FUCA1 (0.53) | FUCA1GAAGBA1MEN1KMT2A | |
| SCHEMBL24325745 | 0.78 | FUCA1 (0.49) | FUCA1CCR5GBA1TACR1KDM4E | |
| SCHEMBL24326663 | 0.78 | FUCA1 (0.49) | FUCA1CCR5GBA1TACR1KDM4E | |
| SCHEMBL24326342 | 0.78 | FUCA1 (0.49) | FUCA1CCR5GBA1TACR1KDM4E | |
| SCHEMBL24325760 | 0.76 | GAA (0.51) | CCR5GAAHTTPAX8TACR1 | |
| SCHEMBL24326331 | 0.76 | GAA (0.51) | CCR5GAAHTTPAX8TACR1 | |
| SCHEMBL3318028 | 0.74 | ACHE (0.46) | FUCA1GAATACR1 | |
| SCHEMBL3318031 | 0.74 | ACHE (0.46) | FUCA1GAATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | FUCA1 2801/4885CCR5 1753/4885GAA 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.